Biotest AG
- Address
- Landsteinerstrasse 5, Dreieichenhain
Sponsor Overview
Specializations
Respiratory Infectious Disease
Clinical research in community-acquired pneumonia and severe pneumonia with a focus on adult hospitalised patients, including cases linked to Coronavirus Disease 2019.
- Non-severe community-acquired pneumonia
- Severe community-acquired pneumonia
- Hospitalised adult patients
The therapeutic interest centres on acute lower respiratory tract infection management in inpatient settings.
COVID-19 Pneumonia
Research activity includes moderate and severe COVID-19 pneumonia, with attention to treatment options for patients requiring hospital care.
- Moderate COVID-19
- Severe COVID-19
- Pneumonia complications
This area reflects an interest in respiratory infections associated with significant pulmonary inflammation and clinical deterioration.
Adjunctive Treatment in Acute Care
The sponsor’s trials examine adjunctive treatment approaches alongside standard of care for acute infectious lung disease.
- Supportive hospital therapy
- Placebo-controlled treatment evaluation
- Clinical outcomes in pneumonia
Interest is directed toward treatment strategies used in addition to established inpatient management.
Mortality and Clinical Outcome Assessment
One research focus is 28-day all-cause mortality in patients with severe pneumonia, alongside broader measures of efficacy and safety in acute respiratory disease.
- All-cause mortality
- Efficacy evaluation
- Safety assessment
This domain addresses clinically meaningful endpoints in serious infectious respiratory illness.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP) |  Austria Belgium Czechia France Germany Hungary Ireland Romania Spain | Recruiting |
| Efficacy and Safety of Trimodulin (BT588) in Hospitalized Adults with Non-Severe CAP or Moderate/Severe COVID-19: A Randomized, Placebo-Controlled Phase III Trial | Austria Belgium France Germany Hungary Latvia Lithuania Portugal Slovakia | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 80 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases2 trials277 other sponsors
Partnered Research Centres
80 centres- Address
- Deltalaan 1, 8800 Roeselare
- Address
- Mudr. Pribulu 412/4, 089 01 Svidník
- Address
- 27 Rue du Faubourg Saint-Jacques, 75014 Paris
- Address
- 46 Rue Henri Huchard, 75877 Paris
- Address
- 4 Rue De La Chine, 75020 Paris
- Address
- Buitenring-Sint-Denijs 30, 9000 Ghent
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Biotest AG.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.